Featured Company /
Relevium Technologies Inc.
The market for self-directed wellness is staggering. A significant part of the $3.7 trillion global wellness market, the nutraceutical segment is forecast by PMMI Business Intelligence to rise from an already impressive $241 billion in 2019 to a staggering $373 billion by 2025. In the U.S. alone, nutraceutical sales were expected to hit $79 billion in 2019.
Nutraceuticals include vitamins and supplements, as well as functional foods and beverages. The industry has been experiencing tremendous growth for decades with little indication that the momentum is going to slow. In fact, with consumers suffering from pill fatigue and desperately seeking alternatives to traditional medicines against the backdrop of cannabis legalization sweeping the globe – including expanded uses in Canada now – and hemp becoming federally legal in the U.S., some additional tailwinds might be blowing.
Medical cannabis is being trumpeted for a litany of health benefits stemming from its compounds (called cannabinoids), including non-psychoactive cannabidiol (CBD).
Legal cannabis is part of the business model of Relevium Technologies Inc. (TSX-Venture:RLV) (OTCQB:RLLVF) The company has dozens of products for sale at some of the world’s biggest retailers, including Walmart.com, eBay and Amazon.com, and is on track to make some significant advances in 2020 thanks to transformational moves it made in 2019.
Like others in the retail space, Relevium is primarily focused on online distribution of its products.
Management prides itself on the ability to identify, evaluate, acquire and operate brands and businesses within the health and wellness markets. To say the company – considering its size ($4 million market cap) – has been ambitious in its growth strategies is putting it mildly.
According to Relevium CEO Aurelio Useche, the company “needed the stretch” to grow and keep up with ever-changing market dynamics.
Currently, Relevium has two subsidiaries in its portfolio in different segments of the wellness market. Rather than try and keep all three directly under the Relevium roof, the company is planning spinouts to unshackle itself from some of the financial burden while still realizing revenues as the majority shareholder of the subsidiaries.
BGX E-Health is a multi-brand company with an extensive line of over-the-counter supplements and skin care products. The company’s product offering includes a cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through the Bioganix®, Push & Pull System® and LeefyLyfe® brands.
Leefy Lyfe is BGX’s OTC cannabidiol Phyto formulated brand combining the same ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD. The company is awaiting a decision from the FDA before it can launch the CBD products into the market.
A loyal customer base on Amazon helps keep Bioganix® amongst the best-selling products in the Health and Personal Care category. Backed by scientific research and superior quality formulations, Bioganix® has become one of the leading dietary supplement brands online.
With the launch of evidence-based products for the heart (CardiaPro) and for the eyes (VisionPro) last year, the Bioganix line includes 56 different products. In 2019, BGX also launched Aloe Vera products through an agreement with Curaloe and soft-launched Push Pull ‘s first anti-aging system, while Leefy Lyfe, an organic hemp-based line launched two SKUs on Amazon.com.
In order to improve margins and control inventory more efficiently, BGX is moving manufacturing to its hometown of Montreal, Quebec. Management is in the final stages of acquiring a biopharma manufacturing company and has shifted to a locally sourced material supplier, Bio V Pharma. Through a new partnership with Bio V Pharma, management foresees better prices, lower expenses and even higher quality, not to mention increased access to domestic and international markets.
The partnership gives BGX access to 400 NPNs (Natural Product Numbers) with Health Canada, which allows for new product launches in the country. Sales in Canada are targeted to begin later this quarter.
Overseas, the manufacturing agreement immediately was followed by a C$1.0 million purchase order from a Middle East customer.
In the coming quarters, the new revenue and improved margins should have a meaningful impact, but it will be realized differently because Relevium intends to execute a spinout/reverse takeover of BGX E-Health into a stand-alone entity with a listing on the CSE as early as next month. Concurrent with the public listing process, New Scope is working to arrange a funding for BGX to get the company additional growth capital.
To the matter of cash flow, the completion of the acquisition of the biopharma company, anticipated before this quarter ends, is expected to add C$3.5 million - C$5.0 million in additional revenue, bringing total annual revenues for Relevium in the range of C$8.0 million - C$10.0 million.
Through its Biocannabix Health Corporation Inc. (BCX) subsidiary, Relevium focuses on nutraceutical and medical foods products infused with targeted cannabinoid formulations for pediatric and geriatric medical applications. Brands under the BCX umbrella include:
• Cannakids (pediatric brand exclusive for the Canadian market)
BCX’s vertically integrated operations are global, with scientific and administrative offices in Montreal, cultivation and extraction operations situated on 20 hectares in Cali, Colombia and a distribution and compliance partnership in Germany (the biggest economy in the European Union).
In Colombia, BCX is conducting a private funding as it completes the acquisition of Lifeline Pharma S.A.S., a Colombian-based cannabis company. Lifeline is in the process of constructing a greenhouse cultivation facility, which is expected to be done during Q1.
In Canada, BCX is in the process of acquiring Weedsense, a late-stage cannabis applicant, with the closing of the transaction expected mid-2020 upon receipt of a sales and processing license from Health Canada.
Relevium fully intends to spin out BCX also, although no timelines have yet been provided.
The spinoffs of BCX and BGX signal the long-term business model coming to fruition for Relevium as it becomes an investing arm (and accelerator of sorts) in the health and wellness industry, using its experience and resources to increase assets of subsidiaries. The model is aligned to unlock additional value through the deployment of profits, albeit acquiring more revenue-generating companies, stock repurchase plans or paying a dividend.
Education Corner Additional Links:
What Are Penny Stocks & How Do You Buy Them?
Which are the Best / Cheapest Penny Stock Brokerages in the U.S. and Canada?
What Kind of Broker Is Right For Me?
What’s The Best Trading Strategy? Fundamental Or Technical Analysis?
Corporate Snapshot:
Relevium Technologies Inc.
Stock Symbol:
CA
Stock Exchange:
TSX-Venture
Sector:
Healthcare
52 Week High:
$0.1300
52 Week Low:
$0.0200
Alt Exchange/Ticker:
OTCQB:RLLVF
Current Stock Quote / Chart / News: Click here
Information as of
February 06, 2020
The market for self-directed wellness is staggering. A significant part of the $3.7 trillion global wellness market, the nutraceutical segment is forecast by PMMI Business Intelligence to rise from an already impressive $241 billion in 2019 to a staggering $373 billion by 2025. In the U.S. alone, nutraceutical sales were expected to hit $79 billion in 2019.
Nutraceuticals include vitamins and supplements, as well as functional foods and beverages. The industry has been experiencing tremendous growth for decades with little indication that the momentum is going to slow. In fact, with consumers suffering from pill fatigue and desperately seeking alternatives to traditional medicines against the backdrop of cannabis legalization sweeping the globe – including expanded uses in Canada now – and hemp becoming federally legal in the U.S., some additional tailwinds might be blowing.
Medical cannabis is being trumpeted for a litany of health benefits stemming from its compounds (called cannabinoids), including non-psychoactive cannabidiol (CBD).
Legal cannabis is part of the business model of Relevium Technologies Inc. (TSX-Venture:RLV) (OTCQB:RLLVF) The company has dozens of products for sale at some of the world’s biggest retailers, including Walmart.com, eBay and Amazon.com, and is on track to make some significant advances in 2020 thanks to transformational moves it made in 2019.
Like others in the retail space, Relevium is primarily focused on online distribution of its products.
Management prides itself on the ability to identify, evaluate, acquire and operate brands and businesses within the health and wellness markets. To say the company – considering its size ($4 million market cap) – has been ambitious in its growth strategies is putting it mildly.
According to Relevium CEO Aurelio Useche, the company “needed the stretch” to grow and keep up with ever-changing market dynamics.
Currently, Relevium has two subsidiaries in its portfolio in different segments of the wellness market. Rather than try and keep all three directly under the Relevium roof, the company is planning spinouts to unshackle itself from some of the financial burden while still realizing revenues as the majority shareholder of the subsidiaries.
BGX E-Health is a multi-brand company with an extensive line of over-the-counter supplements and skin care products. The company’s product offering includes a cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through the Bioganix®, Push & Pull System® and LeefyLyfe® brands.
Leefy Lyfe is BGX’s OTC cannabidiol Phyto formulated brand combining the same ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD. The company is awaiting a decision from the FDA before it can launch the CBD products into the market.
A loyal customer base on Amazon helps keep Bioganix® amongst the best-selling products in the Health and Personal Care category. Backed by scientific research and superior quality formulations, Bioganix® has become one of the leading dietary supplement brands online.
With the launch of evidence-based products for the heart (CardiaPro) and for the eyes (VisionPro) last year, the Bioganix line includes 56 different products. In 2019, BGX also launched Aloe Vera products through an agreement with Curaloe and soft-launched Push Pull ‘s first anti-aging system, while Leefy Lyfe, an organic hemp-based line launched two SKUs on Amazon.com.
In order to improve margins and control inventory more efficiently, BGX is moving manufacturing to its hometown of Montreal, Quebec. Management is in the final stages of acquiring a biopharma manufacturing company and has shifted to a locally sourced material supplier, Bio V Pharma. Through a new partnership with Bio V Pharma, management foresees better prices, lower expenses and even higher quality, not to mention increased access to domestic and international markets.
The partnership gives BGX access to 400 NPNs (Natural Product Numbers) with Health Canada, which allows for new product launches in the country. Sales in Canada are targeted to begin later this quarter.
Overseas, the manufacturing agreement immediately was followed by a C$1.0 million purchase order from a Middle East customer.
In the coming quarters, the new revenue and improved margins should have a meaningful impact, but it will be realized differently because Relevium intends to execute a spinout/reverse takeover of BGX E-Health into a stand-alone entity with a listing on the CSE as early as next month. Concurrent with the public listing process, New Scope is working to arrange a funding for BGX to get the company additional growth capital.
To the matter of cash flow, the completion of the acquisition of the biopharma company, anticipated before this quarter ends, is expected to add C$3.5 million - C$5.0 million in additional revenue, bringing total annual revenues for Relevium in the range of C$8.0 million - C$10.0 million.
Through its Biocannabix Health Corporation Inc. (BCX) subsidiary, Relevium focuses on nutraceutical and medical foods products infused with targeted cannabinoid formulations for pediatric and geriatric medical applications. Brands under the BCX umbrella include:
• Cannakids (pediatric brand exclusive for the Canadian market)
BCX’s vertically integrated operations are global, with scientific and administrative offices in Montreal, cultivation and extraction operations situated on 20 hectares in Cali, Colombia and a distribution and compliance partnership in Germany (the biggest economy in the European Union).
In Colombia, BCX is conducting a private funding as it completes the acquisition of Lifeline Pharma S.A.S., a Colombian-based cannabis company. Lifeline is in the process of constructing a greenhouse cultivation facility, which is expected to be done during Q1.
In Canada, BCX is in the process of acquiring Weedsense, a late-stage cannabis applicant, with the closing of the transaction expected mid-2020 upon receipt of a sales and processing license from Health Canada.
Relevium fully intends to spin out BCX also, although no timelines have yet been provided.
The spinoffs of BCX and BGX signal the long-term business model coming to fruition for Relevium as it becomes an investing arm (and accelerator of sorts) in the health and wellness industry, using its experience and resources to increase assets of subsidiaries. The model is aligned to unlock additional value through the deployment of profits, albeit acquiring more revenue-generating companies, stock repurchase plans or paying a dividend.
Education Corner Additional Links:
What Are Penny Stocks & How Do You Buy Them?
Which are the Best / Cheapest Penny Stock Brokerages in the U.S. and Canada?
What Kind of Broker Is Right For Me?
What’s The Best Trading Strategy? Fundamental Or Technical Analysis?
Forward Looking Statements
This report includes forward-looking statements that reflect current expectations about its future results, performance, prospects and opportunities. Relevium Technologies Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Relevium Technologies Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.
Disclaimer
AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Relevium Technologies Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
© 1999-2024AllPennyStocks.com Media, Inc. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views; opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site.
AllPennyStocks.com has been compensated five thousand dollars by a third-party, Frontier Consulting LLC. for its efforts in presenting the RLV profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates, "believes," or that by statements indicating certain actions "may," "could," or "might" occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.